Moderna unveiled positive early data from its trial assessing its individualized cancer vaccine co-developed with Merck to treat a subset of patients diagnosed with melanoma, a head and neck cancer. The data showed its vaccine, mRNA-4157, combined with Keytruda, exhibited a strong benefit in terms of prolonging survival, according to a presentation at the American Association for Cancer Research annual meeting.